Table 2.

Univariate and multivariate analyses for risk factors of the progressing thrombosis

Variables	Univariate analysis			Multivariate analysis
	OR	95% CI	P value	OR	95% CI	P value
Age (years)	1.109	1.021–1.203	0.014	1.166	1.011–1.346	0.035
Gender (male vs. female)	3.652	0.401–33.242	0.250
Etiology of liver cirrhosis
Hepatitis B virus (yes vs. no)	0.768	0.191–3.089	0.710
Hepatitis C virus (yes vs. no)	1.333	0.126–14.165	0.811
Alcohol abuse (yes vs. no)	2.942	0.739–11.713	0.126
Drug-related liver diseases (yes vs. no)	1.167	0.096–14.126	0.904
Autoimmune liver diseases (yes vs. no)	0.000	0.000–	0.999
History of bleeding (yes vs. no)	0.964	0.235–3.962	0.960
History of EVT (yes vs. no)	2.942	0.739–11.713	0.126
EVT at the first admission (yes vs. no)	1.930	0.436–8.551	0.387
Severe esophageal varices (yes vs. no)	1.083	0.250–4.698	0.915
Laboratory tests
Hemoglobin (g/L)	0.996	0.975–1.017	0.716
White blood cells (109/L)	1.100	0.812–1.489	0.540
Platelet count (109/L)	0.999	0.982–1.017	0.920
Total bilirubin (μmol/L)	1.014	0.975–1.054	0.496
Serum albumin (g/L)	0.902	0.787–1.034	0.138
Alanine aminotransferase (U/L)	0.999	0.985–1.014	0.926
Aspartate aminotransferase (U/L)	0.997	0.982–1.012	0.692
Serum creatinine (μmol/L)	1.050	1.003–1.099	0.037	1.030	0.965–1.099	0.380
Sodium (mmol/L)	0.901	0.714–1.136	0.379
International normalized ratio	2.799	0.333–23.547	0.344
Child–Pugh score	1.625	1.050–2.515	0.029	1.721	0.883–3.353	0.111
MELD score	1.097	0.915–1.314	0.319
Duration between baseline and follow-up contrast-enhanced CT/MRI scans (years)	2.670	1.273–5.600	0.009	3.106	0.969–9.951	0.056
Use of NSBBs (yes vs. no)	4.400	1.107–17.482	0.035	4.084	0.488–34.158	0.194

Italics refer to be statistically significant

EVT esophageal variceal treatment, MELD model for end-stage liver disease, CT computed tomography, MRI magnetic resonance imaging, NSBBs nonselective β-blockers, OR odds ratio, CI confidence interval